BRIVARACETAM

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H20N2O2
Molecular Weight	212.2887
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BRIVARACETAM

Structure Search

SMILES

CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1

InChI

InChIKey=MSYKRHVOOPPJKU-BDAKNGLRSA-N

InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C11H20N2O2
Molecular Weight	212.2887
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:48:27 UTC 2023` Edited by `admin` on `Fri Dec 15 15:48:27 UTC 2023`
Record UNII	U863JGG2IA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BRIVARACETAM

Official Name

English

BRIVARACETAM [MART.]

Common Name

English

brivaracetam [INN]

Common Name

English

Brivaracetam [WHO-DD]

Common Name

English

BRIVARACETAM [USAN]

Common Name

English

BRIVARACETAM [MI]

Common Name

English

UCB 34714

Code

English

BRIVARACETAM [JAN]

Common Name

English

BRIVIACT

Brand Name

English

UCB-34714

Code

English

(2S)-2-[(4R)-2-Oxo-4-propylpyrrolidin-1-yl]butanamide

Systematic Name

English

(2S)-2-((4R)-2-OXO-4-PROPYLTETRAHYDRO-1H-PYRROL-1-YL) BUTANAMIDE

Systematic Name

English

1-PYRROLIDINEACETAMIDE, .ALPHA.-ETHYL-2-OXO-4-PROPYL (.ALPHA.S,4R)-

Common Name

English

BRIVARACETAM [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/05/315

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

WHO-ATC

N03AX23

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

FDA ORPHAN DRUG

207305

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

FDA ORPHAN DRUG

724019

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

FDA ORPHAN DRUG

711119

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

Code System Code Type Description

WIKIPEDIA

BRIVARACETAM

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

DRUG CENTRAL

5068

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

PUBCHEM

9837243

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

CHEBI

133013

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

EPA CompTox

DTXSID00905081

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

ChEMBL

CHEMBL607400

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

INN

8642

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

NDF-RT

N0000192345

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

Epoxide Hydrolase Inhibitors [MoA]

DAILYMED

U863JGG2IA

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

NCI_THESAURUS

C65270

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

EVMPD

SUB25397

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

DRUG BANK

DB05541

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

LACTMED

Brivaracetam

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

USAN

QQ-109

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

RXCUI

1739745

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

FDA UNII

U863JGG2IA

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

CAS

357336-20-0

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

SMS_ID

100000089410

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

MERCK INDEX

m2654

Created by admin on Fri Dec 15 15:48:27 UTC 2023 , Edited by admin on Fri Dec 15 15:48:27 UTC 2023

PRIMARY

Merck Index

Related Record Type Details


					081I12ZA58

CYTOCHROME P450 2C19

METABOLIC ENZYME -> SUBSTRATE

Interaction Type:

MAJOR


					L9DP834D1P

CYTOCHROME P450 2C9

METABOLIC ENZYME -> SUBSTRATE


					U863JGG2IA

EXCRETED UNCHANGED

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					6J2FX2UG0F

SYNAPTIC VESICLE GLYCOPROTEIN 2A

TARGET->LIGAND

Related Record Type Details


					F1D70S9YYX

METABOLITE INACTIVE -> PARENT

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					F1D70S9YYX

METABOLITE INACTIVE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA


					2EO3GFE2R9

BRIVARACETAM ACID

METABOLITE INACTIVE -> PARENT

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					3VQ9G3WT5A

(.ALPHA.S,4R)-.ALPHA.-ETHYL-4-((2S)-2-HYDROXYPROPYL)-2-OXO-1-PYRROLIDINEACETIC ACID

METABOLITE INACTIVE -> PARENT

Related Record Type Details


					D9YE88JDX7

Brivaracetam, (αR,4S)-

IMPURITY -> PARENT

Amount:


					2L499P42DH

3-(Hydroxymethyl)hexanoic acid, (3R)-

IMPURITY -> PARENT

Amount:

Related Record Type Details


					U863JGG2IA

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC